Tirzepatide’s Glowing Obesity Data Steal Show On Lilly’s Earnings Call

 
• By Joseph Haas

Tirzepatide shows ability to produce a mean 52-pound weight loss at 72 weeks, setting up a market showdown with Novo’s Wegovy. Lilly’s quarterly call included reassurance about donanemab for Alzheimer’s and high growth for its COVID-19 antibody.

Head to head battle
Tirzepatide data in obesity may set up head-to-head battle between Lilly, Novo Nordisk • Source: Alamy

More from Earnings

More from Business